Patent ID: 8187595
Filing Date: 2012-05-29
Classification: A61K,A61P,C07K

Abstract:
1. A method of inhibiting IGF-1 actions in a subject in need of treatment for nephropathy, comprising administering to the subject an effective amount of an antibody that: (a) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a human β 3 integrin, wherein said amino acids consist of SEQ ID NO:82; (b) does not specifically bind to the RGD binding site of a human β 3 integrin or utilize the RGD binding site of human β 3 integrin; and (c) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a pig β 3 integrin, wherein said amino acids consist of SEQ ID NO:82, thereby inhibiting IGF-1 actions in the subject and treating the nephropathy in the subject.